Elevated Second Trimester Alpha-Fetoprotein Increases the Risk of Placenta Accreta
Background: Placenta previa-accreta constitutes an increasing clinical problem, whose diagnosis remains challenging in obstetrics. The current work aimed to assess whether second-trimester serum alpha-fetoprotein (AFP) amounts are altered in pregnant women with placenta previa-accreta versus control...
Saved in:
Main Authors: | , , |
---|---|
Format: | Book |
Published: |
IMR Press,
2023-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_e6900322513948dcad7c6e81fa74b9b1 | ||
042 | |a dc | ||
100 | 1 | 0 | |a Fengge Wang |e author |
700 | 1 | 0 | |a Dongmei Man |e author |
700 | 1 | 0 | |a Shiguo Liu |e author |
245 | 0 | 0 | |a Elevated Second Trimester Alpha-Fetoprotein Increases the Risk of Placenta Accreta |
260 | |b IMR Press, |c 2023-11-01T00:00:00Z. | ||
500 | |a 0390-6663 | ||
500 | |a 10.31083/j.ceog5011232 | ||
520 | |a Background: Placenta previa-accreta constitutes an increasing clinical problem, whose diagnosis remains challenging in obstetrics. The current work aimed to assess whether second-trimester serum alpha-fetoprotein (AFP) amounts are altered in pregnant women with placenta previa-accreta versus control values. Methods: A retrospective chart review was performed for 504 pregnant women treated between 1 January 2016 and 28 February 2021. This cohort included 105 placenta previa-accreta and 122 placenta previa control cases, as well as 277 body mass index (BMI)-matched individuals with healthy pregnancy. The multiple of the median (MoM) for AFP was obtained from clinical records. Results: Markedly elevated MoM for AFP was detected in the placenta previa-accreta group compared with the placenta previa control and healthy pregnant control groups (both p < 0.001). Serum AFP levels had a significant positive association with placenta accreta after adjustment for age, BMI, and gestational week at blood collection (β = 0.60; 95% confidence interval [95% CI]: 0.52, 0.68; p < 0.001). In addition, previous cesarean delivery history (β = 3.41; 95% CI: 2.18, 5.34; p < 0.001) also had a significant association with placenta accreta. Conclusions: Elevated second-trimester serum AFP had a positive association with placenta accreta. Such finding suggests a potential role for AFP in detecting pregnancies at high-risk of placenta accreta. This second-trimester biomarker of AFP may help classify women into the high- and low-risk groups for placenta accreta. In addition, we have validated a previous history of cesarean section as a risk factor for accreta in patients with placenta previa. | ||
546 | |a EN | ||
690 | |a alpha-fetoprotein afp | ||
690 | |a placenta accreta | ||
690 | |a second trimester serum | ||
690 | |a association | ||
690 | |a Gynecology and obstetrics | ||
690 | |a RG1-991 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Clinical and Experimental Obstetrics & Gynecology, Vol 50, Iss 11, p 232 (2023) | |
787 | 0 | |n https://www.imrpress.com/journal/CEOG/50/11/10.31083/j.ceog5011232 | |
787 | 0 | |n https://doaj.org/toc/0390-6663 | |
856 | 4 | 1 | |u https://doaj.org/article/e6900322513948dcad7c6e81fa74b9b1 |z Connect to this object online. |